PPAR plus

Genfit S.A. says its GFT14 PPAR alpha agonist may have an advantage over marketed PPAR alpha agonists, or fibrates, which are used for cholesterol reduction, because GFT14 also appears to regulate glucose through its action at an undisclosed G protein-coupled receptor. The company has completed Phase I testing of GFT14 and plans to start a Phase IIa trial in 120 patients in June.

Genfit (Lille, France) specializes in developing molecules that have complementary or synergistic actions at more than one functional target. GFT14 is a case in point. ...